HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on a proprietary arenavirus platform designed to reprogram the body’s immune system. Our platform is designed to directly elicit a powerful and durable response of antigen-specific killer T cells and antibodies, thereby activating essential immune defenses against cancers.